Equilibre BioPharmaceuticals

About Equilibre BioPharmaceuticals

Equilibre BioPharmaceuticals Corp. is a clinical-stage biopharmaceutical company established in 2020 and headquartered in New York. The company concentrates on developing treatments for neurological disorders where existing therapies have shown limited success. It was co-founded by industry veteran Sam Waksal, who has a track record of founding companies like ImClone Systems and Kadmon, and Philip A. Barach, who serves as the Chairman and CEO. Barach previously co-founded and was president of Doubleline Capital. The firm's business model is centered on the research and development of a pipeline of drug candidates, funded through venture capital. To date, the company has raised $52.6 million.

The company's primary focus is on creating drugs that target neuroinflammatory pathways and brain hyperactivation to address conditions with significant unmet clinical needs. Its therapeutic areas of interest include seizure disorders, such as treatment-resistant epilepsy, and traumatic brain injury. Equilibre's pipeline is diversified and built upon an integrated platform designed to develop medications that offer new therapeutic options for patients unresponsive to current treatments. The company's operations are typical of a pre-revenue biopharmaceutical firm, where value is generated through advancing drug candidates through the rigorous phases of clinical trials to eventually secure regulatory approval and commercialize the product. This process involves substantial investment in research, clinical studies, and regulatory affairs.

Equilibre's lead product candidate is EQU-001, a novel, anti-inflammatory, anti-seizure medication intended as an adjunctive therapy for focal seizures in adults with epilepsy. In January 2023, the company announced positive topline results from its Phase 2 clinical trial (EQU-201), which demonstrated the safety, tolerability, and preliminary efficacy of EQU-001. The study showed a dose-dependent reduction in focal seizure frequency, with the 60 mg dose achieving a 44.4% response rate for a 50% or greater reduction in seizures. Following these results, Equilibre has been implementing a larger, 300-patient Phase 3 study (EQU-202) across multiple centers in the US, EU, UK, and Israel to further test 20 mg and 60 mg doses against a placebo. The company also has a collaboration with SeraNovo BV to enhance the formulation of poorly water-soluble active pharmaceutical ingredients, aiming to improve bioavailability for its neurological drug candidates.